Chronic Hepatitis B (CHB) Market Expected to Reach $6.2 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Chronic Hepatitis B (CHB) Market," The chronic hepatitis b (CHB) market was valued at $4.6 billion in 2021, and is estimated to reach $6.2 billion by 2031, growing at a CAGR of 3% from 2022 to 2031.

Hepatitis B is a viral infection that causes liver inflammation and damage. Inflammation is swelling that occurs when tissues of the body become injured or infected. Inflammation can damage organs. Chronic hepatitis B is a long-lasting infection. According to National Institutes of Health (NIH), about 90% of infants infected with hepatitis B develop a chronic infection. About 25 to 50% of children infected between the ages of 1 and 5 years develop chronic infections. However, only about 5% of people first infected as adults develop chronic hepatitis B.

The surge in the prevalence of hepatitis B and improvements in healthcare infrastructure drive the growth of the Chronic Hepatitis B Market Size. For instance, in April 2022, according to Bristol Myers & Squibb, each year, nearly 1 million people worldwide died due to hepatitis B or hepatitis c. In addition, rise in awareness about hepatitis infection and advancements in hepatitis treatment boost the expansion of the Chronic Hepatitis B Industry.

The strict government regulations on blood transfusion and blood banks contribute to the growth of the Chronic Hepatitis B Market Size. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory. and initiatives taken by the government and non-government organizations propel the growth of the Chronic Hepatitis B Market Size.

Furthermore, Chronic Hepatitis B Market Trends that drive the growth of the chronic hepatitis B market include R&D for the development of chronic hepatitis B, an increase in drug class approvals, and new product launches in the market. In addition, advancements in the diagnosis of hepatitis B propel the growth of the market. For instance, in May 2022, Abbott, a leading pharmaceutical company, announced the launch of HBsAg Next Qualitative Assay for early detection of the Hepatitis B virus (HBV) in India. Early identification of HBV infections not only helps in preventing or delaying the progression of advanced liver diseases but also reduces the risk of transmission. Furthermore, the rise in healthcare expenditure and improvements in healthcare facilities in developing nations contribute to the growth of the Chronic Hepatitis B Industry.

The chronic hepatitis B market is segmented into drug class, gender, distribution channel, and region.

Based on the drug class segment, the market is divided into antivirals and immune modulators. The antivirals segment dominated the Chronic Hepatitis B Market Share in 2021, and this trend is expected to continue during the Chronic Hepatitis B Market Forecast period, owing to the increase in the prevalence of hepatitis B.

Based on gender segment, the market is categorized into male and female. The male segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to the high prevalence rate of male and an increase in blood transfusion rate.

Depending on the distribution channel segment, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to an increase in healthcare expenditure and a rise in the number of drug stores & retail pharmacies.

North America accounted for a majority of the global chronic hepatitis B market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to the rising prevalence of hepatitis B, the well-established healthcare infrastructure, and the presence of key players in the region. Asia-Pacific is anticipated to witness lucrative growth during the Chronic Hepatitis B Market Analysis period owing to an increase in the number of blood banks, growth in the geriatric population, and a high population base.

Key findings of the study

• By drug class, the antivirals segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.
• By gender, the male segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.
• By distribution channel, the drug stores & retail pharmacies segment was the highest contributor to the market in 2021.
• Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period